CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lisata Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lisata Therapeutics Inc
110 Allen Road, Second Floor
Phone: (908) 229-2590p:908 229-2590 BASKING RIDGE, NJ  07920  United States Ticker: LSTALSTA
Business Summary
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Gregory B.Brown 71 2/16/2017 10/10/2016
Chief Executive Officer, Director David J.Mazzo 66 9/15/2022 1/5/2015
Executive Vice President - Research & Development, Chief Medical Officer Kristen K.Buck 49 9/1/2021 9/1/2021
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
China Biopharmaceuticals Holdings, Inc. Suite 602, China Life Tower Beijing China
Progenitor Cell Therapy, LLC 4 Pearl Court Allendale NJ United States

Business Names
Business Name
Athelos Corporation
California Stem Cell, Inc.
CendR Platform™
7 additional Business Names available in full report.

General Information
Number of Employees: 25 (As of 12/31/2023)
Outstanding Shares: 8,394,903 (As of 11/12/2024)
Shareholders: 292
Stock Exchange: NASD
Federal Tax Id: 222343568
Fax Number: (845) 818-3588
Email Address: info@cneostem.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024